22OCT

Universal Quantum's record round opens Singapore lab

2 min read

16:30UTC

The Sussex spinout's Series A of more than $100m is the largest by a UK-headquartered quantum company, and its first new site will be in Singapore.

← Back to Stryker agrees option to buy CMR Surgical Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Universal Quantum's record round brings in Singapore's state investor and a Singapore lab.

Universal Quantum, a University of Sussex spinout, raised more than $100m (about £75m) in a Series A announced around 8 October, the largest by a UK-headquartered quantum company⁠¹. It builds modular trapped-ion quantum computers, which compute with single charged atoms held in place by electric fields. DCVC of Silicon Valley co-led with London's Firgun Ventures. Singapore's state investor EDBI joined, alongside Artal, Integral GlobalTech, IAG Capital and Roblox chief executive Dave Baszucki.

The money opens a research centre in Singapore before sites in the US, Japan and the company's Hamburg hub; Singapore is its first site outside Europe. A month earlier, Open Cosmos had raised €300m from a European syndicate with the UK's security investment fund inside it. Universal Quantum's record round names Singapore's state investor and no British state investor.

Deep Analysis

In plain English

Universal Quantum is a company that grew out of the University of Sussex. It is trying to build quantum computers, which use the strange rules of atomic physics to solve some problems that ordinary computers cannot. Its machines trap single charged atoms, called ions, and use them as the computer's basic units. The company has raised more than $100m, about £75m. Part of the money will open a research centre in Singapore. Singapore's government investment arm, EDBI, is among the investors.

Deep Analysis

Root Causes

Trapped-ion machines need vacuum systems, lasers and precision electronics that few British suppliers make at volume. Building the next generation means locating where suppliers, engineers and subsidies cluster.

State investors such as EDBI usually trade capital for local activity. A research centre in Singapore is the kind of commitment that comes with a Singaporean state cheque.

What could happen next?

Consequence
Universal Quantum's first research site outside Europe goes to Singapore, ahead of planned sites in the US and Japan.
Risk
Engineering headcount may grow faster abroad than in Sussex if foreign state partners attach site commitments to future rounds.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: Oxford Ionics, a trapped-ion spinout from the University of Oxford, agreed in 2025 to sell to the American firm IonQ for about $1.08bn. The last British trapped-ion company to reach this scale ended inside a US group.

Counter-parallel: Oxford Nanopore Technologies took foreign and domestic money for years but floated in London in 2021 and kept its headquarters and manufacturing in Oxford. A British deep-tech spinout can stay British-led if it lists at home.

Consensus view: The Quantum Insider and tech.eu treat the round as proof that modular trapped-ion designs can raise growth-sized money in Europe, with DCVC, a deep-tech specialist from Silicon Valley, co-leading alongside the quantum-focused London fund Firgun Ventures.

Counter-view: Singapore's National Quantum Strategy, launched in 2024 with close to S$300m, is built to pull research centres into the city-state, and EDBI is the state investor that delivers that policy. On that reading the round's location decision follows Singaporean industrial policy rather than the company's British base.

Key tension: Whether Universal Quantum's next hiring and fabrication spend follows its Sussex roots or the capital that arrived with conditions attached elsewhere.

Sources:Tech.eu

Mentions:Universal Quantum →DCVC →EDBI →University of Oxford →Integral GlobalTech →Dave Baszucki →Roblox →Singapore →Hamburg →Open Cosmos →Oxford Ionics →Japan →London →IonQ →Oxford Nanopore →University of Sussex →Firgun Ventures →

First Reported In

Update #16 · Stryker agrees option to buy CMR Surgical

Tech.eu· 22 Oct 2026

Read original →

Causes and effects

Caused by

Open Cosmos raises €300m, no US name

Universal Quantum's round named Singapore's state investor a month after Open Cosmos raised with UK state money inside its syndicate.

Occurred 14 Sept 2026

Read story →

This Event

Universal Quantum's record round opens Singapore lab

Britain's largest quantum Series A carries Singapore's state investor and sends the company's first site outside Europe to Asia.

Different Perspectives

Abu Dhabi Investment Council

The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

CDP Venture Capital

CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.

EDBI

Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.

Forbion

Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.

British Business Bank

The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.

Stryker Corporation

Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.